Skip to main content
SpringerLink
Log in

Herpes Zoster and the Zoster Eye Disease Study (ZEDS)

  • Chapter
  • First Online:
Foundations of Corneal Disease

  • 712 Accesses

Abstract

Herpes zoster (HZ), including herpes zoster ophthalmicus (HZO), is a very common disease caused by the reactivation of varicella zoster virus (VZV), with serious, potentially vision- and life-threatening complications. Alarmingly, the incidence of HZ is increasing while age at onset is decreasing, but it is preventable by vaccination. When HZ does occur, current recommended treatment reduces eye disease, but does not prevent chronic and/or recurrent eye disease, nor postherpetic neuralgia. New treatment with prolonged suppressive antiviral treatment for HZO is under investigation in a multicenter randomized controlled clinical trial supported by the National Eye Institute to determine whether or not it is effective in reducing complications, including eye disease and/or postherpetic neuralgia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lee HL, Yeo M, Choi GH, Lee JY, Kim JS, Shin DI, et al. Clinical characteristics of headache or facial pain prior to the development of acute herpes zoster of the head. ClinNeurolNeurosurg. 2017;152:90–4.

    Google Scholar 

  2. Lewis GW. Zoster sine herpete. Br Med J. 1958;2(5093):418–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Food and Drug Administration. Zoster Vaccine Live. 2006. Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm136941.htm.

  4. Food and Drug Administration. Zoster Vaccine Recombinant, Adjuvanted. 2017. Available from: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm581491.htm.

  5. Centers for the Disease Control and Prevention. Shingles (Herpes Zoster). Available from: https://www.cdc.gov/shingles.

  6. Suaya JA, Chen SY, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1(2):ofu049.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2Suppl):S3–12.

    Article  PubMed  Google Scholar 

  8. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.

    Article  PubMed  Google Scholar 

  9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–30.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ghaznawi N, Virdi A, Dayan A, Hammersmith KM, Rapuano CJ, Laibson PR, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology. 2011;118(11):2242–50.

    Article  PubMed  Google Scholar 

  12. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis. 2010;50(7):1000–5.

    Article  PubMed  Google Scholar 

  13. Chan AY, Conrady CD, Ding K, Dvorak JD, Stone DU. Factors associated with age of onset of herpes zoster ophthalmicus. Cornea. 2015;34(5):535–40.

    Article  PubMed  Google Scholar 

  14. Davies EC, Pavan-Langston D, Chodosh J. Herpes zoster ophthalmicus: declining age at presentation. Br J Ophthalmol. 2016;100(3):312–4.

    Article  PubMed  Google Scholar 

  15. Kawai K, Yawn BP, Wollan P, Harpaz R. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gershon AA. Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future? J Infect. 2017;74(Suppl 1):S27–s33.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kawai K, Yawn BP. Risk factors for herpes zoster: asystematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806–21.

    Article  PubMed  Google Scholar 

  18. Matthews A, Turkson M, Forbes H, Langan SM, Smeeth L, Bhaskaran K. Statin use and the risk of herpes zoster: a nested case-control study using primary care data from the U.K. Clinical Research Practice Datalink. Br J Dermatol. 2016;175(6):1183–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Borkar DS, Tham VM, Esterberg E, Ray KJ, Vinoya AC, Parker JV, et al. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2013;120(3):451–6.

    Article  PubMed  Google Scholar 

  20. Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54.

    Article  PubMed  Google Scholar 

  21. Chen MH, Wei HT, Su TP, Li CT, Lin WC, Chang WH, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014;76(4):285–91.

    Article  PubMed  Google Scholar 

  22. Hess TM, Lutz LJ, Nauss LA, Lamer TJ. Treatment of acute herpetic neuralgia. A case report and review of the literature. Minn Med. 1990;73(4):37–40.

    CAS  PubMed  Google Scholar 

  23. Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88(6):562–70.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hoang-Xuan T, Buchi ER, Herbort CP, Denis J, Frot P, Thenault S, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99(7):1062–70; discussion 70–1.

    Article  CAS  PubMed  Google Scholar 

  25. Tran KD, Falcone MM, Choi DS, Goldhardt R, Karp CL, Davis JL, et al. Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity. Ophthalmology. 2016;123(7):1469–75.

    Article  PubMed  PubMed Central  Google Scholar 

  26. He Y, de Melo Franco R, Kron-Gray MM, Musch DC, Soong HK. Outcomes of cataract surgery in eyes with previous herpes zoster ophthalmicus. J Cataract Refract Surg. 2015;41(4):771–7.

    Article  PubMed  Google Scholar 

  27. Breuer J, Pacou M, Gautier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology. 2014;83(2):e27–33.

    Article  PubMed  Google Scholar 

  28. Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis. 2014;58(11):1497–503.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nagel MA, Gilden D. The relationship between herpes zoster and stroke. CurrNeurolNeurosci Rep. 2015;15(4):16.

    Google Scholar 

  30. Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84(19):1948–55.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Buckingham EM, Foley MA, Grose C, Syed NA, Smith ME, Margolis TP, et al. Identification of herpes zoster-associated temporal arteritis among cases of giant cell arteritis. Am J Ophthalmol. 2018;187:51–60.

    Article  PubMed  Google Scholar 

  32. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.

    Article  CAS  PubMed  Google Scholar 

  34. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a vaccine safety Datalink study. J Intern Med. 2012;271(5):510–20.

    Article  CAS  PubMed  Google Scholar 

  36. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9.

    Article  PubMed  Google Scholar 

  38. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872–5.

    Article  PubMed  Google Scholar 

  39. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.

    Article  PubMed  Google Scholar 

  40. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.

    Article  CAS  PubMed  Google Scholar 

  41. Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148–54.

    Article  CAS  PubMed  Google Scholar 

  42. Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, et al. Immunogenicity and safety of an Adjuvantedherpes zoster subunit vaccine coadministeredwith seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Oxman MN, Harbecke R, Koelle DM. Clinical usage of the adjuvantedherpes zoster subunit vaccine (HZ/su): revaccination of recipients of live attenuated zoster vaccine and coadministrationwith a seasonal influenza vaccine. J Infect Dis. 2017;216(11):1329–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, et al. Immunogenicity and safety of the HZ/suadjuvantedherpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88–93.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum VaccinImmunother. 2017;13(5):1051–8.

    Google Scholar 

  47. Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations –United States, 2015. MMWRSurveillSumm(Washington, DC: 2002). 2017;66(11):1–28.

    Google Scholar 

  48. Lu PJ, O'Halloran A, Williams WW, Harpaz R. National and state-specific shingles vaccination among adults aged ≥60 years. Am J Prev Med. 2017;52(3):362–72.

    Article  PubMed  Google Scholar 

  49. Dommasch ED, Joyce CJ, Mostaghimi A. Trends in Nationwide herpes zoster emergency department utilization from 2006 to 2013. JAMA Dermatol. 2017;153(9):874–81.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.

    Article  PubMed  Google Scholar 

  51. Hurley LP, Bridges CB, Harpaz R, Allison MA, ST OL, Crane LA, et al. Physician attitudes toward adult vaccines and other preventive practices, United States, 2012. Public Health Rep (Washington, DC: 1974). 2016;131(2):320–30.

    Article  Google Scholar 

  52. Elkin ZP, Cohen EJ, Goldberg JD, Li X, Castano E, Gillespie C, et al. Improving adherence to national recommendations for zoster vaccination through simple interventions. Eye Contact Lens. 2014;40(4):225–31.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Tsui E, Gillespie C, Perskin M, Zabar S, Wu M, Cohen EJ. Evaluating physician attitudes and practices regarding herpes zoster vaccination. Cornea. 2018;37(8):947–51.

    Article  PubMed  Google Scholar 

  54. Ophthalmology AAo. Recommendations for herpes zoster vaccine for patients 50 years and older – 2016. Available from: https://www.aao.org/clinical-statement/recommendations-herpes-zoster-vaccine-patients-50.

  55. Le P, Rothberg MB. Cost-effectiveness of the recommendations of the advisory committee on immunization practices for the recombinant adjuvantedzoster subunit vaccine. JAMA Intern Med. 2018;178(9):1277–8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Harpaz R, Leung J. When zoster hits close to home: impact of personal zoster awareness on zoster vaccine uptake in the U.S. Vaccine. 2017;35(27):3457–60.

    Article  PubMed  Google Scholar 

  57. Bonanni P, Bonaccorsi G, Lorini C, Santomauro F, Tiscione E, Boccalini S, et al. Focusing on the implementation of 21st century vaccines for adults. Vaccine. 2018;36(36):5358–65.

    Article  PubMed  Google Scholar 

  58. Pavan-Langston D, Yamamoto S, Dunkel EC. Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. ArchOphthalmol (Chicago, Ill: 1960). 1995;113(11):1381–5.

    Article  CAS  Google Scholar 

  59. Hu AY, Strauss EC, Holland GN, Chan MF, Yu F, Margolis TP. Late varicella-zoster virus dendriform keratitis in patients with histories of herpes zoster ophthalmicus. Am J Ophthalmol. 2010;149(2):214–20.e3.

    Article  PubMed  Google Scholar 

  60. Takase H, Kubono R, Terada Y, Imai A, Fukuda S, Tomita M, et al. Comparison of the ocular characteristics of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Jpn J Ophthalmol. 2014;58(6):473–82.

    Article  CAS  PubMed  Google Scholar 

  61. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998;339(5):300–6.

    Google Scholar 

  62. Lo D, Jeng B, Gilliespie C, Wu M, Cohen E. Current practice patterns and opinions in the management of recent onset or chronic Herpes Zoster Ophthalmicus of Zoster Eye Disease Study investigators. Cornea. 2019;38(1):13–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NYU School of Medicine, NYU Langone Health, Department of Ophthalmology, New York, NY, USA

    Elisabeth J. Cohen

  2. University of Maryland School of Medicine, Baltimore, MD, USA

    Bennie H. Jeng

Authors
  1. Elisabeth J. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bennie H. Jeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth J. Cohen .

Editor information

Editors and Affiliations

  1. Louis Block Professor Chair, Department of Ophthalmology and Visual Science, The University of Chicago Medicine & Biological Sciences, Chicago, IL, USA

    Kathryn Colby

  2. Claes H. Dohlman Professor of Ophthalmology, Harvard Medical School, Cornea & Refractive Surgery, Massachusetts Eye & Ear, Boston, MA, USA

    Reza Dana

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cohen, E.J., Jeng, B.H. (2020). Herpes Zoster and the Zoster Eye Disease Study (ZEDS). In: Colby, K., Dana, R. (eds) Foundations of Corneal Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-25335-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25335-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25334-9

  • Online ISBN: 978-3-030-25335-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation